文献速递流行病学与生物统计真实世界研究与卫生经济

慢性阻塞性肺疾病患者结局预测的预后模型:系统综述与批判性评估

Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal.
PubMed 文献 · BMJ · 2019-10-04

该系统综述检索PubMed至2018年11月并手工检索参考文献,纳入228篇文献,描述408个预后模型的开发、38个模型的外部验证及20个其他疾病模型的验证。模型开发场景以门诊(59%)、住院(38%)和急诊(3%)为主,最常见终点为死亡率(51%)、慢阻肺急性加重风险(10%)和指数住院后再入院风险(9%)。仅7个模型总体偏倚风险低,12个模型C统计量汇总估计范围为0.611至0.769。

要点

  • 共纳入228篇文献,描述408个预后模型的开发,仅38个模型经外部验证。
  • 最常见预测因子为年龄(41%)、第一秒用力呼气容积(21%)、性别(18%)、体质指数(16%)和吸烟(16%)。
  • 仅7个模型总体偏倚风险低:ADO、B-AE-D、B-AE-D-C、扩展ADO、更新ADO、更新BODE和Bertens等开发的模型。

核心结论

  • 该研究对慢阻肺患者结局预测的预后模型进行了详细映射和评估,发现模型开发存在若干方法学缺陷且外部验证率低。
  • 未来研究应聚焦于通过更新和外部验证改进现有模型,并通过影响研究评估这些预后模型在临床实践中应用的安全性、临床效果和成本效果。

研究设计与样本

  • 系统综述,检索PubMed截至2018年11月并手工检索纳入文章的参考文献,纳入开发、验证或更新慢阻肺患者预测模型且聚焦任何潜在临床结局的研究。
  • 系统检索共获得228篇符合条件的文献,描述408个预后模型的开发、38个模型的外部验证以及20个为慢阻肺以外疾病开发的预后模型的验证。
  • 408个预后模型在三种临床场景中开发:门诊(n=239;59%)、住院患者(n=155;38%)和急诊科就诊患者(n=14;3%)。

主要发现

  • 408个预后模型中最常见终点为死亡率(n=209;51%)、慢阻肺急性加重风险(n=42;10%)和指数住院后再入院风险(n=36;9%)。
  • 最常用预测因子为年龄(n=166;41%)、第一秒用力呼气容积(n=85;21%)、性别(n=74;18%)、体质指数(n=66;16%)和吸烟(n=65;16%)。
  • 408个模型中100个(25%)进行了内部验证,91个(23%)检验了所开发模型的校准度;286个(70%)模型无可用模型呈现,仅56个(14%)模型以完整方程呈现。
  • 311个(76%)模型报告了C统计量的模型区分度;38个模型进行了外部验证,但仅12个由完全独立团队完成验证。
  • 仅7个模型根据PROBAST总体偏倚风险低:ADO、B-AE-D、B-AE-D-C、扩展ADO、更新ADO、更新BODE和Bertens等开发的模型;对12个预后模型的C统计量进行Meta分析,汇总估计范围为0.611至0.769。

关键数值与推荐

  • PROBAST总体偏倚风险低的模型为ADO、B-AE-D、B-AE-D-C、扩展ADO、更新ADO、更新BODE和Bertens等开发的模型。
  • 12个预后模型C统计量Meta分析的汇总估计范围为0.611至0.769。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To map and assess prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease (COPD). DESIGN: Systematic review. DATA SOURCES: PubMed until November 2018 and hand searched references from eligible articles. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Studies developing, validating, or updating a prediction model in COPD patients and focusing on any potential clinical outcome. RESULTS: The systematic search yielded 228 eligible articles, describing the development of 408 prognostic models, the external validation of 38 models, and the validation of 20 prognostic models derived for diseases other than COPD. The 408 prognostic models were developed in three clinical settings: outpatients (n=239; 59%), patients admitted to hospital (n=155; 38%), and patients attending the emergency department (n=14; 3%). Among the 408 prognostic models, the most prevalent endpoints were mortality (n=209; 51%), risk for acute exacerbation of COPD (n=42; 10%), and risk for readmission after the index hospital admission (n=36; 9%). Overall, the most commonly used predictors were age (n=166; 41%), forced expiratory volume in one second (n=85; 21%), sex (n=74; 18%), body mass index (n=66; 16%), and smoking (n=65; 16%). Of the 408 prognostic models, 100 (25%) were internally validated and 91 (23%) examined the calibration of the developed model. For 286 (70%) models a model presentation was not available, and only 56 (14%) models were presented through the full equation. Model discrimination using the C statistic was available for 311 (76%) models. 38 models were externally validated, but in only 12 of these was the validation performed by a fully independent team. Only seven prognostic models with an overall low risk of bias according to PROBAST were identified. These models were ADO, B-AE-D, B-AE-D-C, extended ADO, updated ADO, updated BODE, and a model developed by Bertens et al. A meta-analysis of C statistics was performed for 12 prognostic models, and the summary estimates ranged from 0.611 to 0.769. CONCLUSIONS: This study constitutes a detailed mapping and assessment of the prognostic models for outcome prediction in COPD patients. The findings indicate several methodological pitfalls in their development and a low rate of external validation. Future research should focus on the improvement of existing models through update and external validation, as well as the assessment of the safety, clinical effectiveness, and cost effectiveness of the application of these prognostic models in clinical practice through impact studies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017069247.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Bellou V, Belbasis L, Konstantinidis AK, et al. Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal. BMJ. 2019. PMID: 31585960. doi:10.1136/bmj.l5358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。